Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 2RecruitingNCT04922567

Second Affiliated Hospital, Zhejiang University, School of Medicine289 enrolled

Overview

This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)

This is a randomized, multi-center, open-label study to compare efficacy and safety of L-CHOP with standard CHOP regimen in patients with previously untreated PTCL. Study subjects are patients with histologically proven PTCL. Patients are randomized 1:1 to receive either cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles or Lenalidomide plus CHOP (L-CHOP) administered in 3 week cycles for 6 cycles. In the L-CHOP arm, Lenalidomide will be administered at a dose of 25mg po on day 1-10 every 3 weeks. This study is divided into three phases: screening phase, treatment phase and follow-up phase. Patients will receive study drug(s) for up to 6 cycles, or until unacceptable toxicity will develop or progression or voluntary with drawl. Adverse event of every treatment cycle will be recorded. Therapy efficacy will be evaluated after finishing 3 cycles and finishing 6 cycles therapy. Patients will be followed until disease progression, died or 3 years from the last patient randomized.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

289

Conditions

Peripheral T-Cell Lymphoma Lenalidomide CHOP

Interventions

LenalidomideDRUG

25mg po on day 1-10

CyclophosphamideDRUG

750mg/m² iv on day1

DoxorubicinDRUG

50mg/m² iv on day 1

Vincristine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL not otherwise specified, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, enteropathy-associated T cell lymphoma, Monomorphic epitheliotropic intestinal T-cell lymphoma, Nodal peripheral T-cell lymphoma with T-follicular helper phenotype and Follicular T-cell lymphoma). 2. Males and females of 18 years of age to 80 years of age. 3. Patients have not received anti-tumor therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. 5. Fit chemotherapy indications and basic requirements, including no obvious abnormal function of heart, liver, lung and kidney: creatine ≤2.0×ULN, total bilirubin ≤2.0mg/dl, transaminases≤3×ULN. 6. Normal peripheral hemogram: absolute neutrophil count(ANC)≥1.5×10\^9/L, hemoglobin(Hb)≥90g/L, platelet(PLT)≥100×10\^12/L. 7. None of other serious disease conflict with the therapeutic regimen. 8. None of other malignant tumor. 9. Pregnancy test of women at reproductive age must be negative. 10. Estimated survival time ≥ 3 months with good compliance. 11. Voluntary participation, cooperate with the experimental observation, and sign a written informed consent. Exclusion Criteria: 1. Patients with the following PTCL subtypes are excluded; extranodal natural killer(NK)/T-cell lymphoma, T-prolymphocytic leukemia, T large granular lymphocytic leukemia, chronic lymphoproliferative disorder of NK cells, aggressive NK-cell leukemia, adult T-cell leukemia/ lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous T cell lymphoma, breast implant-associated anaplastic large-cell lymphoma. 2. Transformed lymphoma. 3. Patients with other malignancies in the past or now; or secondary lymphoma triggered by chemotherapy or radiotherapy of other malignancies. 4. Already initiated lymphoma therapy (except for the prephase treatment specified for this study). 5. Patients with primary central nervous system lymphoma or lymphoma involving central nervous system. 6. Patients who have central nervous system or meninges involvements. 7. Candidate for hematopoietic stem cell transplantation. 8. Known hypersensitivity to medications to be used. 9. Hemogram abnormality: ANC\<1.5×10\^9/L; or hemoglobin\<90 g/L; or PLT\<100×10\^9/L. 10. Known hepatic and renal insufficiency (creatine\>2.0×ULN, total bilirubin\>2.0 mg/dl，transaminases\>3.0×ULN). 11. Patients with decompensated heart failure; or with dilated cardiomyopathy; or with coronary heart disease of non-corresponding ST-segment in ECG diagnosis; or with myocardial infarction within 6 months. 12. Patients with serious uncontrolled acute infection need to be treated with antibody therapies, or antiviral therapies; or serious accompanying disorder or impaired organ function. 13. Know HIV-positivity; or HbsAg positivity; or hepatitis C virus-Ab positivity. 14. Pregnancy or lactation period. 15. Patients who participated in other clinical trials within 3 months. 16. The researchers considered that patients should not be in this trial.

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Objective Response rate

complete response (CR) and partial response (PR) rates, using the standard response criteria( 2014 Lugano criteria)

Time frame: At the end of Cycle 6 (each cycle is 21 days)

Secondary Outcomes

Progression Free Survival

from date of inclusion to date of progression, relapse, or death from any cause

Time frame: 3 years

Overall Survival

From the date of inclusion to date of death, irrespective of cause

Time frame: 3 years

Adverse Events

Any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure

Time frame: 3 years

Central Contacts

Wenbin Qian, Prof.

CONTACT

+86-13605801032 qianwb@zju.edu.cn

Xianggui Yuan, Dr.

CONTACT

+86-13989883884 yuanxg@zjue.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.